- Home
- SRTAW vs AYTU Comparison
SRTAW vs AYTU Comparison
Compare SRTAW & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRTAW
- AYTU
- Stock Information
- Founded
- SRTAW N/A
- AYTU N/A
- Country
- SRTAW United States
- AYTU United States
- Employees
- SRTAW N/A
- AYTU N/A
- Industry
- SRTAW
- AYTU Biotechnology: Pharmaceutical Preparations
- Sector
- SRTAW
- AYTU Health Care
- Exchange
- SRTAW Nasdaq
- AYTU Nasdaq
- Market Cap
- SRTAW 16.3M
- AYTU 18.8M
- IPO Year
- SRTAW 2019
- AYTU N/A
- Fundamental
- Price
- SRTAW $0.18
- AYTU $2.33
- Analyst Decision
- SRTAW
- AYTU Strong Buy
- Analyst Count
- SRTAW 0
- AYTU 3
- Target Price
- SRTAW N/A
- AYTU $9.17
- AVG Volume (30 Days)
- SRTAW N/A
- AYTU 381.3K
- Earning Date
- SRTAW N/A
- AYTU 11-12-2025
- Dividend Yield
- SRTAW N/A
- AYTU N/A
- EPS Growth
- SRTAW N/A
- AYTU N/A
- EPS
- SRTAW N/A
- AYTU N/A
- Revenue
- SRTAW N/A
- AYTU $66,382,000.00
- Revenue This Year
- SRTAW N/A
- AYTU N/A
- Revenue Next Year
- SRTAW N/A
- AYTU $19.03
- P/E Ratio
- SRTAW N/A
- AYTU N/A
- Revenue Growth
- SRTAW N/A
- AYTU 1.84
- 52 Week Low
- SRTAW N/A
- AYTU $0.95
- 52 Week High
- SRTAW N/A
- AYTU $2.82
- Technical
- Relative Strength Index (RSI)
- SRTAW N/A
- AYTU 55.70
- Support Level
- SRTAW N/A
- AYTU $1.65
- Resistance Level
- SRTAW N/A
- AYTU $1.98
- Average True Range (ATR)
- SRTAW 0.00
- AYTU 0.16
- MACD
- SRTAW 0.00
- AYTU 0.01
- Stochastic Oscillator
- SRTAW 0.00
- AYTU 64.35
About AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.